136 related articles for article (PubMed ID: 28238095)
1. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
[TBL] [Abstract][Full Text] [Related]
2. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
He Y; Wang Y; Liu H; Xu X; He S; Tang J; Huang Y; Miao X; Wu Y; Wang Q; Cheng C
Leuk Res; 2015 Dec; 39(12):1428-36. PubMed ID: 26453405
[TBL] [Abstract][Full Text] [Related]
3. Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.
Fei M; Hang Q; Hou S; Ruan C
Int J Hematol; 2013 Oct; 98(4):446-55. PubMed ID: 24037419
[TBL] [Abstract][Full Text] [Related]
4. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.
Miao X; Xu X; Wu Y; Zhu X; Chen X; Li C; Lu X; Chen Y; Liu Y; Huang J; Wang Y; He S
Tumour Biol; 2016 Jan; 37(1):1369-78. PubMed ID: 26298725
[TBL] [Abstract][Full Text] [Related]
6. Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells.
Tang J; Ji L; Wang Y; Huang Y; Yin H; He Y; Liu J; Miao X; Wu Y; Xu X; He S; Cheng C
Int J Hematol; 2015 Jul; 102(1):25-34. PubMed ID: 25804841
[TBL] [Abstract][Full Text] [Related]
7. Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.
Zhu X; Ouyang Y; Zhong F; Wang Q; Ding L; Zhang P; Chen L; Liu H; He S
Oncol Rep; 2017 Jan; 37(1):622-630. PubMed ID: 27840970
[TBL] [Abstract][Full Text] [Related]
8. Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.
Fei M; Hang Q; Hou S; He S; Ruan C
Mol Cell Biochem; 2014 Jan; 386(1-2):177-87. PubMed ID: 24170542
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
[TBL] [Abstract][Full Text] [Related]
10. EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma.
Ding L; Shen Y; Ni J; Ou Y; Ou Y; Liu H
Tumour Biol; 2017 Mar; 39(3):1010428317694298. PubMed ID: 28351297
[TBL] [Abstract][Full Text] [Related]
11. Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.
Liu J; Wang Y; He S; Xu X; Huang Y; Tang J; Wu Y; Miao X; He Y; Wang Q; Liang L; Cheng C
Hematology; 2016 Dec; 21(10):603-612. PubMed ID: 27319807
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
13. RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
Liu H; Ding L; Shen Y; Zhong F; Wang Q; Xu X
Int J Biol Macromol; 2016 Oct; 91():115-22. PubMed ID: 27189701
[TBL] [Abstract][Full Text] [Related]
14. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
[TBL] [Abstract][Full Text] [Related]
15. ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions.
Schlienger S; Ramirez RA; Claing A
Cell Signal; 2015 Mar; 27(3):403-15. PubMed ID: 25530216
[TBL] [Abstract][Full Text] [Related]
16. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
Hazlehurst LA; Damiano JS; Buyuksal I; Pledger WJ; Dalton WS
Oncogene; 2000 Sep; 19(38):4319-27. PubMed ID: 10980607
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).
Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y
BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545
[TBL] [Abstract][Full Text] [Related]
18. The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells.
Xu X; Liu J; Shen C; Ding L; Zhong F; Ouyang Y; Wang Y; He S
Eur J Haematol; 2017 Jan; 98(1):4-12. PubMed ID: 26710889
[TBL] [Abstract][Full Text] [Related]
19. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.
He S; Miao X; Wu Y; Zhu X; Miao X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Wang Y; Xu X
J Cancer Res Clin Oncol; 2016 Mar; 142(3):561-72. PubMed ID: 26498772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
